L‑Carnitine
Quaternary ammonium compound, endogenously synthesized from lysine + methionine precursors, mitochondrial long-chain fatty acid shuttle (carnitine palmitoyltransferase I/II). Gulewitsch + Krimberg 1905 isolation, Sigma-Tau 1985 FDA primary carnitine deficiency Rx; bodybuilding off-label since the 1990s, mainstream OTC fat-burner supplement since the 2000s. WADA: allowed, NADA Germany 2018 monitored above 50 mg/kg IV-bolus.
WHAT IS L-CARNITINE?
Detailed overview
L-Carnitine is a quaternary ammonium compound that the human body synthesizes endogenously at ~25 mg/day via a hepatic + renal enzyme cascade from lysine and methionine precursors. It was originally isolated by the Russian biochemists Gulewitsch and Krimberg in 1905 from muscle tissue (hence the name 'carnitine' from 'caro/carnis' = meat). Only the L-isomer is biologically active; the D-isomer is enzymatically inert and a cardiotoxicity signal. The 1985 Sigma-Tau (Italian pharma) FDA approval covered the primary carnitine deficiency Rx indication; bodybuilding off-label use began in the 1990s, and since the 2000s OTC 'fat-burner supplement' has been a mainstream category. The mechanism rests on the CoA-mediated mitochondrial inner-membrane transport of long-chain fatty acids (LCFAs) via the carnitine palmitoyltransferase I/II (CPT-I/II) enzyme shuttle system – this is the rate-limiting step of β-oxidation. Stephens 2007 (Am J Physiol PMID 17331998), the classic IV-clamp methodology trial, demonstrated that supraphysiological oral doses >1 g/day do NOT raise the endogenous synthetic level, but with chronic loading (3-4 weeks at 2 g/day) muscle-tissue concentration can be raised 2-3x in the presence of carbohydrate co-ingestion-mediated insulin-stimulated muscle uptake. Oral bioavailability is low (~15%); the IM/SC injectable form provides 100% bioavailability and is 4-6x dose-equivalent over oral. WADA: 'allowed' on the 2025 prohibited list, but NADA Germany 2018 elevated >50 mg/kg IV-bolus dosing into a monitored category (potential blood-doping-marker context).
Mechanism of action
Long-chain fatty acid CoA-mediated mitochondrial shuttle (CPT-I/II), rate-limiting step of β-oxidation
Dosing
Oral 500-2000 mg/day split 3x; IM/SC 1-2 g 2-3x/week for cutting cycles
Half-life
~15 hours (parent compound), muscle loading steady-state 3-4 weeks chronic
Onset
Oral 1-2 hours (low bioavailability ~15%); IM/SC 30-60 minutes (100% bioavailability)
Legal status
FDA + EMA Rx (primary carnitine deficiency), OTC supplement category globally. WADA: allowed, NADA Germany 2018 monitored above 50 mg/kg IV-bolus.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Gastrointestinal upset: diarrhea, nausea, abdominal cramps, heartburn, especially at oral doses >2 g/day (the most common, dose-dependent side effect).
- Fishy body odor (trimethylaminuria-like): gut bacteria produce trimethylamine from carnitine, causing a fishy smell in sweat, breath and urine, typically at >2 g/day.
- Elevated serum TMAO (trimethylamine-N-oxide) with chronic high-dose use (>2 g/day, 6+ months); an atherosclerosis risk-marker, though its causal role is debated (Koeth 2013 vs Yancey 2018).
- Injectable form (IM/SC): painful injection (PIP), local irritation from the quaternary-ammonium vehicle, rarely sterile abscess or transient local redness and warmth.
- Rare allergic/histamine-release reaction with parenteral dosing (flushing, itching, hypotension); a 0.5 g test dose is advised for the first IM/SC injection.
- Thyroid interaction: carnitine inhibits peripheral T4-to-T3 conversion, which in patients treated for hypothyroidism may worsen symptoms or require levothyroxine dose adjustment (Benvenga 2001).
- Warfarin/anticoagulant interaction: chronic carnitine dosing can raise INR, increasing bleeding risk; INR monitoring is required (Martinez 2007).
- Rarely restlessness, mild stimulant-like feeling and sleep disturbance at higher doses; through lowering of the seizure threshold, increased seizure frequency has been reported in predisposed individuals.
Contraindications · 7
- Seizure disorder (epilepsy) or a condition predisposing to seizures: carnitine may rarely lower the seizure threshold and increase seizure frequency, so caution is required.
- Severe renal failure / dialysis (ESRD): dose adjustment is needed due to reduced renal clearance, and D,L-carnitine (racemic OTC) must be strictly avoided because of the D-isomer's cardiotoxic/myasthenic risk.
- Concurrent warfarin or other coumarin anticoagulant: due to the risk of elevated INR and bleeding, only with close INR monitoring under medical supervision.
- Treated hypothyroidism (on levothyroxine): carnitine weakens the peripheral action of thyroid hormone, which can reduce treatment efficacy; dose monitoring is required.
- Known hypersensitivity to L-carnitine (or any component of the formulation); for the parenteral form, a prior histamine/allergic reaction to injection.
- Pregnancy and breastfeeding without an Rx indication: supplement-dose is FDA category B, but high-dose IM/SC parenteral use is not recommended without medical indication.
- Overlap with carnitine supplementation during valproate therapy: valproate can cause carnitine deficiency and is often therapeutically supplemented, so cycle-level supplementation only in consultation with the treating physician.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle
Stephens FB, Constantin-Teodosiu D, Greenhaff PL.
Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans
Wall BT, Stephens FB, Constantin-Teodosiu D et al.
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth RA, Wang Z, Levison BS et al.
L-carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress
Kraemer WJ, Volek JS, French DN et al.
Effects of L-carnitine on weight loss and body composition: a meta-analysis of 37 randomized controlled clinical trials
Talenezhad N, Mohammadi M, Ramezani-Jolfaie N et al.
Telegram
Have a question about L‑Carnitine?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.